FratantoniJCHallCWNeufeldEF. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science. 1968;162(3853):570–572.
2.
HobbsJRHugh-JonesKBarrettAJ. Reversal of clinical features of Hurler’s disease and biochemical improvement after treatment by bone-marrow transplantation. Lancet. 1981;2(8249):709–712.
3.
KrivitW. Correction of inborn errors of metabolism by bone marrow transplant. Basic Life Sci. 1983;25:63–76.
4.
KrivitWPierpontMEAyazK. Bone-marrow transplantation in the Maroteaux-Lamy syndrome (mucopolysaccharidosis type VI). Biochemical and clinical status 24 months after transplantation. N Engl J Med. 1984;311(25):1606–1611.
5.
WhitleyCBRamsayNKKerseyJHKrivitW. Bone marrow transplantation for Hurler syndrome: assessment of metabolic correction. Birth Defects Orig Artic Ser. 1986;22(1):7–24.
6.
KrivitWWhitleyCB. Bone marrow transplantation for genetic diseases. N Engl J Med. 1987;316(17):1085–1087.
7.
KrivitWShapiroEHoogerbruggePMMoserHW. State of the art review. Bone marrow transplantation treatment for storage diseases. Keystone. January 23, 1992. Bone Marrow Transplant. 1992;10(suppl 1):87–96.
8.
PetersCShapiroEGAndersonJ. Hurler syndrome: II. Outcome of HLA-genotypically identical sibling and HLA-haploidentical related donor bone marrow transplantation in fifty-four children. The Storage Disease Collaborative Study Group. Blood. 1998;91(7):2601–2608.
9.
BraunlinEARoseAGHopwoodJJCandelRDKrivitW. Coronary artery patency following long-term successful engraftment 14 years after bone marrow transplantation in the Hurler syndrome. Am J Cardiol. 2001;88(9):1075–1077.
10.
BraunlinEAStaufferNRPetersCH. Usefulness of bone marrow transplantation in the Hurler syndrome. Am J Cardiol. 2003;92(7):882–886.
11.
StabaSLEscolarMLPoeM. Cord-blood transplants from unrelated donors in patients with Hurler’s syndrome. N Engl J Med. 2004;350(19):1960–1969.
12.
OrchardPJBlazarBRWagnerJCharnasLKrivitWTolarJ. Hematopoietic cell therapy for metabolic disease. J Pediatr. 2007;151(4):340–346.
13.
HansenMDFilipovichAHDaviesSM. Allogeneic hematopoietic cell transplantation (HCT) in Hurler’s syndrome using a reduced intensity preparative regimen. Bone Marrow Transplant. 2008;41(4):349–353.
14.
BoelensJJRochaVAldenhovenM. Risk factor analysis of outcomes after unrelated cord blood transplantation in patients with hurler syndrome. Biol Blood Marrow Transplant. 2009;15(5):618–625.
15.
PrasadVKKurtzbergJ. Transplant outcomes in mucopolysaccharidoses. Semin Hematol. 2010;47(1):59–69.
16.
de RuMHBoelensJJDasAM. Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J Rare Dis. 2011;6:55.
17.
BoelensJJAldenhovenMPurtillD. Outcomes of transplantation using various hematopoietic cell sources in children with Hurler syndrome after myeloablative conditioning. Blood. 2013;121(19):3981–3987.
18.
EisengartJBRudserKDTolarJ. Enzyme replacement is associated with better cognitive outcomes after transplant in Hurler syndrome. J Pediatr. 2013;162(2):375–380.e1.
19.
MitchellRNivison-SmithIAnazodoA. Outcomes of haematopoietic stem cell transplantation for inherited metabolic disorders: a report from the Australian and New Zealand Children’s Haematology Oncology Group and the Australasian Bone Marrow Transplant Recipient Registry. Pediatr Transplant. 2013;17(6):582–588.
20.
AldenhovenMJonesSABonneyD. Hematopoietic cell transplantation for mucopolysaccharidosis patients is safe and effective: results after implementation of international guidelines. Biol Blood Marrow Transplant. 2015;21(6):1106–1109.
21.
AldenhovenMWynnRFOrchardPJ. Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multi-center study. Blood. 2015;125:2164–2172.
22.
ColettiHYAldenhovenMYelinKPoeMDKurtzbergJEscolarML. Long-term functional outcomes of children with Hurler syndrome treated with unrelated umbilical cord blood transplantation. JIMD Rep. 2015;20:77–86.
23.
GhoshAMillerWOrchardPJ. Enzyme replacement therapy prior to haematopoietic stem cell transplantation in mucopolysaccharidosis Type I: 10 year combined experience of 2 centres. Mol Genet Metab. 2016;117(3):373–377.
24.
LumSHMillerWPJonesS. Changes in the incidence, patterns and outcomes of graft failure following hematopoietic stem cell transplantation for Hurler syndrome. Bone Marrow Transplant. 2017;52(6):846–853.
25.
RodgersNJKaizerAMMillerWPRudserKDOrchardPJBraunlinEA. Mortality after hematopoietic stem cell transplantation for severe mucopolysaccharidosis type I: the 30-year University of Minnesota experience. J Inherit Metab Dis. 2017;40(2):271–280.
26.
LiptonMLockmanLARamsayNKKerseyJHJacobsonRIKrivitW. Bone marrow transplantation in metachromatic leukodystrophy. Birth Defects Orig Artic Ser. 1986;22(1):57–67.
27.
KrivitWLiptonMELockmanLA. Prevention of deterioration in metachromatic leukodystrophy by bone marrow transplantation. Am J Med Sci. 1987;294(2):80–85.
28.
KrivitWShapiroEKennedyW. Treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation. N Engl J Med. 1990;322(1):28–32.
29.
KolodnyEHRaghavanSKrivitW. Late-onset Krabbe disease (globoid cell leukodystrophy): clinical and biochemical features of 15 cases. Dev Neurosci. 1991;13(4-5):232–239.
30.
DhunaAToroCTorresFKennedyWRKrivitW. Longitudinal neurophysiologic studies in a patient with metachromatic leukodystrophy following bone marrow transplantation. Arch Neurol. 1992;49(10):1088–1092.
31.
LoesDJPetersCKrivitW. Globoid cell leukodystrophy: distinguishing early-onset from late-onset disease using a brain MR imaging scoring method. AJNR Am J Neuroradiol. 1999;20(2):316–323.
32.
KocONDayJNiederMGersonSLLazarusHMKrivitW. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant. 2002;30(4):215–222.
33.
EscolarMLPoeMDProvenzaleJM. Transplantation of umbilical-cord blood in babies with infantile Krabbe’s disease. N Engl J Med. 2005;352(20):2069–2081.
34.
CanigliaMRanaIPintoRM. Allogeneic bone marrow transplantation for infantile globoid-cell leukodystrophy (Krabbe’s disease). Pediatr Transplant. 2002;6(5):427–431.
35.
MariaBLDeidrickKMMoserHNaiduS. Leukodystrophies: pathogenesis, diagnosis, strategies, therapies, and future research directions. J Child Neurol. 2003;18(9):578–590.
36.
StyczynskiJCheungYKGarvinJ. Outcomes of unrelated cord blood transplantation in pediatric recipients. Bone Marrow Transplant. 2004;34(2):129–136.
37.
McGrawPLiangLEscolarMMukundanSKurtzbergJProvenzaleJM. Krabbe disease treated with hematopoietic stem cell transplantation: serial assessment of anisotropy measurements—initial experience. Radiology. 2005;236(1):221–230.
38.
RingdenORembergerMSvahnBM. Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center. Transplantation. 2006;81(5):718–725.
39.
EichlerFVan HarenK. Immune response in leukodystrophies. Pediatr Neurol. 2007;37(4):235–244.
40.
GorgMWilckWGranitznyB. Stabilization of juvenile metachromatic leukodystrophy after bone marrow transplantation: a 13-year follow-up. J Child Neurol. 2007;22(9):1139–1142.
41.
SevinCAubourgPCartierN. Enzyme, cell and gene-based therapies for metachromatic leukodystrophy. J Inherit Metab Dis. 2007;30(2):175–183.
42.
BiffiALucchiniGRovelliASessaM. Metachromatic leukodystrophy: an overview of current and prospective treatments. Bone Marrow Transplant. 2008;42(suppl 2):S2–S6.
43.
LimZYHoAYAbrahamsS. Sustained neurological improvement following reduced-intensity conditioning allogeneic haematopoietic stem cell transplantation for late-onset Krabbe disease. Bone Marrow Transplant. 2008;41(9):831–832.
44.
PiersonTMBonnemannCGFinkelRSBuninNTennekoonGI. Umbilical cord blood transplantation for juvenile metachromatic leukodystrophy. Ann Neurol. 2008;64(5):583–587.
45.
DuffnerPKCavinessVSJrErbeRW. The long-term outcomes of presymptomatic infants transplanted for Krabbe disease: report of the workshop held on July 11 and 12, 2008, Holiday Valley, New York. Genet Med. 2009;11:450–454.
46.
de HossonLDvan de WarrenburgBPPreijersFW. Adult metachromatic leukodystrophy treated by allo-SCT and a review of the literature. Bone Marrow Transplant. 2011;46:1071–1076.
47.
MiyakeNMiyakeKKarlssonSShimadaT. Successful treatment of metachromatic leukodystrophy using bone marrow transplantation of HoxB4 overexpressing cells. Mol Ther. 2010;18(7):1373–1378.
48.
OrchardPJTolarJ. Transplant outcomes in leukodystrophies. Semin Hematol. 2010;47(1):70–78.
YagasakiHKatoMIshigeMShichinoHChinMMugishimaH. Successful cord blood transplantation in a 42-day-old boy with infantile Krabbe disease. Int J Hematol. 2011;93(4):566–568.
51.
GelinasJLiaoPLehmanAStocklerSSirrsS. Child neurology: Krabbe disease: a potentially treatable white matter disorder. Neurology. 2012;79(19):e170–e172.
MartinHRPoeMDProvenzaleJMKurtzbergJMendizabalAEscolarML. Neurodevelopmental outcomes of umbilical cord blood transplantation in metachromatic leukodystrophy. Biol Blood Marrow Transplant. 2013;19:616–624.
54.
MirandaCOBritesPMendes SousaMTeixeiraCA. Advances and pitfalls of cell therapy in metabolic leukodystrophies. Cell Transplant. 2013;22(2):189–204.
55.
SharpMELauleCNantelS. Stem cell transplantation for adult-onset krabbe disease: report of a case. JIMD Rep. 2013;10:57–59.
56.
BoucherAAMillerWShanleyR. Long-term outcomes after allogeneic hematopoietic stem cell transplantation for metachromatic leukodystrophy: the largest single-institution cohort report. Orphanet J Rare Dis. 2015;10:94.
57.
KrivitWSungJHShapiroEGLockmanLA. Microglia: the effector cell for reconstitution of the central nervous system following bone marrow transplantation for lysosomal and peroxisomal storage diseases. Cell Transplant. 1995;4(4):385–392.
58.
CogleCRYachnisATLaywellED. Bone marrow transdifferentiation in brain after transplantation: a retrospective study. Lancet. 2004;363(9419):1432–1437.
59.
ArayaKSakaiNMohriI. Localized donor cells in brain of a Hunter disease patient after cord blood stem cell transplantation. Mol Genet Metab. 2009;98(3):255–263.
60.
AubourgPBlancheSJambaqueI. Reversal of early neurologic and neuroradiologic manifestations of X-linked adrenoleukodystrophy by bone marrow transplantation. N Engl J Med. 1990;322(26):1860–1866.
61.
MahmoodARaymondGVDubeyPPetersCMoserHW. Survival analysis of haematopoietic cell transplantation for childhood cerebral X-linked adrenoleukodystrophy: a comparison study. Lancet Neurol. 2007;6(8):687–692.
OkamuraKWatanabeTOnishiT. Successful allogeneic unrelated bone marrow transplantation using reduced-intensity conditioning for the treatment of X-linked adrenoleukodystrophy in a one-yr-old boy. Pediatr Transplant. 2009;13(1):130–133.
64.
MillerWPRothmanSMNasceneD. Outcomes after allogeneic hematopoietic cell transplantation for childhood cerebral adrenoleukodystrophy: the largest single-institution cohort report. Blood. 2011;118(7):1971–1978.
65.
MillerWPMantovaniLFMuzicJ. Intensity of MRI gadolinium enhancement in cerebral adrenoleukodystrophy: a biomarker for inflammation and predictor of outcome following transplantation in higher risk patients. AJNR Am J Neuroradiol. 2016;37(2):367–372.
66.
PierpontEIEisengartJBShanleyR. Neurocognitive trajectory of boys who received a hematopoietic stem cell transplant at an early stage of childhood cerebral adrenoleukodystrophy. JAMA Neurol. 2017;74(6):710–717.
67.
PierpontEIMcCoyEKingKE. Post-transplant adaptive function in childhood cerebral adrenoleukodystrophy. Ann Clin Transl Neurol. 2018;5(3):252–261.
68.
KleinKAKrivitWWhitleyCB. Poor cognitive outcome of eleven children with Sanfilippo syndrome after bone marrow transplantation and successful engraftment. Bone Marrow Transplant. 1995;15(suppl 1):S176–S181.
69.
McKinnisEJSulzbacherSRutledgeJCSandersJScottCR. Bone marrow transplantation in Hunter syndrome. J Pediatr. 1996;129(1):145–148.
70.
VellodiAYoungECooperALidchiVWinchesterBWraithJE. Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis. 1999;22(5):638–648.
71.
HusainAMEscolarMLKurtzbergJ. Neurophysiologic assessment of mucopolysaccharidosis III. Clin Neurophysiol. 2006;117(9):2059–2063.
72.
ValayannopoulosVWijburgFA. Therapy for the mucopolysaccharidoses. Rheumatology (Oxford). 2011;50(suppl 5):v49–v59.
73.
TanakaAOkuyamaTSuzukiY. Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol Genet Metab. 2012;107(3):513–520.
74.
WellingLMarchalJPvan HasseltPvan der PloegATWijburgFABoelensJJ. Early umbilical cord blood-derived stem cell transplantation does not prevent neurological deterioration in mucopolysaccharidosis type III. JIMD Rep. 2015;18:63–68.
75.
GiuglianiRFederhenAVairoF. Emerging drugs for the treatment of mucopolysaccharidoses. Expert Opin Emerg Drugs. 2016;21:9–26.
76.
KubaskiFYabeHSuzukiY. Hematopoietic stem cell transplantation for patients with mucopolysaccharidosis II. Biol Blood Marrow Transplant. 2017;23(10):1795–1803.
EisengartJBRudserKDXueY. Long-term outcomes of systemic therapies for Hurler syndrome: an international multicenter comparison [published online ahead of print March 8, 2018]. Genet Med. doi:10.1038/gim.2018.29.
80.
WynnRFWraithJEMercerJ. Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J Pediatr. 2009;154(4):609–611.
81.
O’LearyMKrailoMAndersonJRReamanGHChildren’s OncologyG. Progress in childhood cancer: 50 years of research collaboration, a report from the Children’s Oncology Group. Semin Oncol. 2008;35(5):484–493.
82.
SmithMASeibelNLAltekruseSF. Outcomes for children and adolescents with cancer: challenges for the twenty-first century. J Clin Oncol. 2010;28(15):2625–2634.
